



Attorney Docket No. 1330.1038C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

			i i
In re Pa	atent Applica	ation of:	
Lauren	ce HONARV	/AR, et al. 16/756,387/	/
Gontinu	uation of App	olication No.: 99/348,161	Group Art Unit:
Filed: J	anuary 14, 2	2004	Examiner:
For:	DECISION	MANAGEMENT SYSTEM WI	TH AUTOMATED STRATEGY OPTIMIZATION
		INFORMATION DISCLO	DSURE STATEMENT
PO Box	ssioner for F k 1450 dria, VA 223	·	
Sir:			
the sub	ed certain inf oject U.S. pa	ormation which the Examiner	provisions of 37 CFR § 1.56, there is hereby may consider material to the examination of that the Examiner make this information of of the subject application.
1.	Enclosures	accompanying this Information	n Disclosure Statement are:
	1a.	application or a PCT Internat English language translation each non-English language p Explanations of Relevancy o providing a concise explanat List of Copending Application	(complete or relevant portion(s)) attached to
2. 🔲	This Infor		s filed under 37 CFR §1.97(b):
		•	2a or 2b or 2c or 2d)
	2a. 🗌	Continued Prosecution Appli	
	2b. 🗌	§ 1.491 in an international ap	
	2c.		Office Action on the merits; or Office Action after the filing of a Request for

Continued Examination under § 1.114.

3.	U	specified Action und	mation Disclosure Statement is filed under 37 CFR § 1.97(c) after the period in paragraph 2 above but before the mailing date of any of a Final Office der § 1.113, a Notice of Allowance under § 1.311 or an action that otherwise osecution in the application, AND (Check either Item 3a or 3b; Item 3b to be checked if any reference known for more than 3 months) The §1.97(e) Statement in Item 5 below is applicable; OR The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is: enclosed. to be charged to Deposit Account No. 19-3935.	
4.		specified 4a.	mation Disclosure Statement is filed under 37 CFR §1.97(d) after the period in paragraph 3 above, but on or before payment of the Issue Fee, AND The § 1.97(e) Statement in Item 5 below is applicable; AND The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is: enclosed to be charged to Deposit Account No. 19-3935.	
			·	
5.		Statemen	t under § 1.97(e) (applicable if Item 3a or Item 4a is checked)	
		_	(Check either Item 5a or 5b)	
		5a.	In accordance with 37 CFR § 1.97(e)(1), it is stated that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. In accordance with 37 CFR § 1.97(e)(2), it is stated that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known by any individual designated in §1.56(c) more than three months prior to the filing of this Information	
			Disclosure Statement.	
6.	\boxtimes	This is a continuation/divisional/continuation-in-part application under 37 CFR § 1.53(b).		
			(Check appropriate Items 6a and/or 6b)	
		6a: ⊠	Copies of the publications listed on the attached Form PTO-1449 which were previously cited in prior application Serial No. 09/348,161, filed on July 7, 1999, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, have been omitted pursuant to 37 CFR § 1.98(d).	
		6b. 🗌	Copies of the publications listed on the attached Form PTO-1449 which were not previously cited in prior application Serial No, filed on, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, are provided herewith.	

7.	Ш	Continued Examination under 37 CFR § 1.53(d) or a Request for Continued Examination under 37 CFR 1.114.			
			(Check either Item 7a or 7b)		
		7a. [7b. [The Issue Fee has not been paid. A Petition to Withdraw from issue under 37 CFR § 1.313(c) is filed concurrently herewith or has been granted. A continuation/divisional application under 37 CFR § 1.53(d) or a Request for Continued Examination under 37 CFR 1.114, after payment of the Issue Fee, is proper in accordance with 37 CFR § 1.53(d)(1)(ii) or 37 CFR 1.114(a), respectively.		
8.		This is	a Supplemental Information Disclosure Statement. (Check either Item 8a or 8b)		
		8a. [This Supplemental Information Disclosure Statement under 37 CFR § 1.97(f) supplements the Information Disclosure Statement filed on A bona fide attempt was made to comply with 37 CFR § 1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental IDS car		
		8b. [be considered as if properly filed on This Supplemental Information Disclosure Statement is timely filed within one (1) month of the Notice under 37 CFR § 1.97 and 1.98, mailed		
9.			dance with 37 CFR § 1.98, a concise explanation of what is presently bod to be the relevance of each non-English language publication is: (Check appropriate Items 9a, 9b, 9c and/or 9d)		
		9a. [satisfied because all non-English language publications were cited on the enclosed "English language version of the search report or action which indicates the degree of relevance found by the foreign office". (See MPEP § 609, Minimum Requirements for an Information Disclosure Statement, Part A(3): Concise Explanation of Relevance, 8th Ed.)		
		9b. [9c. [set forth in the application. satisfied because an English language translation (complete or relevant		
		9d. [portion(s)) is attached to each non-English language publication. enclosed as Attachment 1(e), hereto.		
10.	be th	e, mate an sea	ession is made that the information cited in this Statement is, or is considered to rial to patentability nor a representation that a search has been made (other rch report(s) from a counterpart foreign application or a PCT International tenort if submitted herewith) 37 CFR 88 1 97(g) and (h)		

11. The Commissioner is authorized to credit any overpayment or charge any additional fee required under 37 CFR § 1.17 for this Information Disclosure Statement to Deposit Account No. 19-3935.

Respectfully submitted,

STAAS & HALSEY LLP

Dated: January / , 200

1201 New York Ave. M.W., Suite 700

Washington, D.C. 20005 Telephone: (202) 434-1500 Facsimile: (202) 434-1501 By:

Paul I. Kravetz

Registration No. 35,230